1 Practical Significance of Pei's "Lanzhou Formula" in Treating Chronic Myeloid Leukemia

1 Practical Significance of Pei's "Lanzhou Formula" in Treating Chronic Myeloid Leukemia

Chronic myeloid leukemia (commonly referred to as CML) is a malignant clonal disease of hematopoietic stem cells, with most patients presenting with emaciation, fatigue, abdominal distension, abdominal pain, accompanied by hepatosplenomegaly and enlarged lymph nodes. According to its natural disease course, it can be divided into chronic phase, accelerated phase, and blast crisis phase; typically, the chronic phase lasts 1–4 years before progressing to the accelerated and blast crisis phases, the latter being considered the terminal stage. Modern medicine currently lacks a curative treatment for this disease, usually relying on oral hydroxyurea, maphalan, and other chemotherapeutic agents, as well as interferon therapy, but these treatments often have significant toxic side effects, making them intolerable for some patients. In recent years, molecular targeted therapies such as imatinib and bone marrow transplantation have become the preferred options for treating this disease, yet certain toxic side effects, heavy financial burdens, and the high risks associated with transplantation prevent most patients from accepting them. In recent years, with the development of traditional Chinese medicine, TCM has increasingly attracted attention in the treatment of CML due to its advantages of effectively alleviating symptoms, delaying relapse, having fewer toxic side effects, and being less likely to induce drug resistance.